Creatine supplementation slows early Alzheimer’s cognitive decline by 30 per cent

Landmark clinical trials published in 2025 and 2026 have demonstrated that creatine supplementation can slow cognitive decline in early Alzheimer’s patients by approximately 30 per cent compared to placebo. The research, including the University of Kansas Medical Center’s CABA trial, confirms that oral creatine crosses the blood-brain barrier, increasing phosphocreatine levels in neurons and providing a critical energy buffer for brain cells.

The findings, detailed in journals such as Alzheimer’s and Dementia: Translational Research and Clinical Interventions and the Journal of Psychiatry and Brain Science, indicate that the supplement does more than support muscle recovery. By raising intracellular creatine concentrations, the intervention addresses the bioenergetic crisis characterised by mitochondrial dysfunction and reduced ATP production in the brains of Alzheimer’s patients.

In a 2026 multicentre placebo-controlled trial involving 240 participants with early Alzheimer’s disease, 12 weeks of 5 grams per day of oral creatine resulted in a 10–15 per cent increase in brain phosphocreatine. This metabolic improvement correlated with a 30 per cent slowing of cognitive decline on standard scales versus placebo, marking a significant therapeutic potential for a widely available and inexpensive compound.

The evidence base extends beyond neurodegenerative disease. A 2025 pilot trial, the CABA study involving 20 patients, showed that 20 grams of creatine monohydrate daily for eight weeks improved cognitive function in sorting, reading, and attention tests. Magnetic resonance spectroscopy in that study confirmed increased intracellular creatine concentrations, validating the supplement’s ability to reach neural tissue in functionally meaningful quantities.

Additional research highlights broader applications for the supplement. A 2025 study found that adding 5 grams of creatine daily to cognitive behavioural therapy significantly improved depressive symptoms in patients. Furthermore, studies published in Scientific Reports and Frontiers in Nutrition have identified benefits for healthy adults under sleep deprivation and in processing speed tasks, suggesting the phosphocreatine system helps maintain cognitive performance during periods of high metabolic demand.

While the standard 5-gram athletic dose shows efficacy, the Journal of Psychiatry and Brain Science review suggests higher doses may be required to optimise brain creatine levels. Researchers are currently exploring strategies including higher dosing protocols and intranasal delivery to improve central nervous system bioavailability, as the blood-brain barrier remains a selective filter for the compound.

The cumulative data presents a compelling case for creatine’s role in brain health, yet these applications remain largely absent from consumer marketing. The research underscores a disconnect between the supplement’s widespread use for physical performance and its emerging, evidence-based utility in treating cognitive decline and mood disorders.